Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate for oral aluminum phosphide poisoning
IRCT20250412065294N1Phase 2Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of sevelamer carbonate in Aluminium phosphide poisoning (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Mortality rate, Time of ICU stay and 1 more. Started May 2025; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20250412065294N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250412065294N1.